Juno Therapeutics Inc shares surged  in their market debut Friday after a flurry of demand for the years last expected new offering led the biotech firm to price above its alreadyboosted range  Juno which develops cancer treatments that use the bodys own immune system to fight the disease began trading Friday on the Nasdaq at  a share after pricing  million shares at  Shares
  